Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Randomized, Comparative Pharmacokinetic Study of Bolus Intravenous Lidocaine 0.7 mg/kg, Lidocaine Patch 1.8%, and Lidocaine Patch 5% (Lidoderm) in Healthy Subjects

Next Previous
X
Search
Trial Profile

Phase 1, Randomized, Comparative Pharmacokinetic Study of Bolus Intravenous Lidocaine 0.7 mg/kg, Lidocaine Patch 1.8%, and Lidocaine Patch 5% (Lidoderm) in Healthy Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 27 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lidocaine (Primary) ; Lidocaine (Primary) ; Lidocaine
  • Indications Postherpetic neuralgia
  • Focus Pharmacokinetics; Registrational
  • Sponsors Scilex Pharmaceuticals

    • Most Recent Events

    • 28 Feb 2018 According to a Sorrento Therapeutics media release, the U.S. Food and Drug Administration (FDA) has approved ZTlid (lidocaine topical system) 1.8% for the relief of pain associated with post-herpetic neuralgia (PHN), also referred to as post-shingles pain.
    • 12 Sep 2017 According to a Sorrento Therapeutics media release, SCILEX Pharmaceuticals Inc. a majority-owned subsidiary of Sorrento, has received from the U.S. Food and Drug Administration (FDA) acknowledgement of receipt of its recently resubmitted New Drug Application (NDA) for ZTlido(lidocaine patch 1.8%) which has been considered a complete, class 2 response to the prior action letter. The PDUFA date is set for February 28, 2018 .
    • 29 Aug 2017 According to a Sorrento Therapeutics media release, data from this trial was used to resubmit the NDA and all FDA comments related to the initial NDA submission for the lead product candidate, ZTlido (lidocaine patch 1.8%) were responded by SCILEX Pharmaceuticals Inc.(a majority-owned subsidiary of Sorrento).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top